1800-272-662
Shopping Cart 0
countryflagAU
Login

Algorae Pharmaceuticals Ltd

Healthcare AU 1AI

0.015AUD
0.001(7.14%)

Last update at 2026-03-13T03:07:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0050.02
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap23.98M
  • Volume301277
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.57920M
  • Revenue TTM0.14M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.14M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -1.54014M -2.09556M -2.10766M -2.37203M -1.90545M
Minority interest - - - - -
Net income -0.80296M -2.09556M -2.10766M -1.95730M -1.46059M
Selling general administrative 0.84M 1.31M 0.82M 0.91M 0.67M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - 0.00056M 0.00074M 0.00478M
Ebit - - -2.13005M -2.36449M -2.28362M
Ebitda -1.54014M -2.20072M -2.12949M -2.36375M -2.27884M
Depreciation and amortization - - 0.00056M 0.00074M 0.00478M
Non operating income net other - - - - -
Operating income -1.69351M -2.20072M -2.13005M -2.36449M -2.28362M
Other operating expenses 1.69M 2.20M 2.13M 2.38M 2.28M
Interest expense - - - 0.00341M 0.38M
Tax provision -0.73718M 0.00000M 0.00000M -0.41473M -0.44486M
Interest income 0.02M 0.02M 0.04M 0.00341M 0.00760M
Net interest income - 0.13M 0.04M 0.00341M 0.00760M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.73718M - -0.04257M -0.41473M -0.44486M
Total revenue 0.14M 0.13M 0.04M 0.00341M 0.27M
Total operating expenses 1.69M 2.20M 2.13M 2.38M 2.28M
Cost of revenue - - - - -
Total other income expense net 0.15M 0.11M -0.02018M -0.00754M 0.38M
Discontinued operations - - - - -
Net income from continuing ops - -2.09556M -2.10766M -1.95730M -1.46059M
Net income applicable to common shares -0.80296M -2.09556M -2.10766M -1.95730M -1.46059M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 2.40M 3.19M 4.21M 4.27M 1.64M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.04M 0.04M - - -
Total liab 0.17M 0.18M 0.45M 0.24M 0.27M
Total stockholder equity 2.23M 3.01M 3.76M 4.03M 1.38M
Deferred long term liab - - - - -
Other current liab - - 0.27M 0.19M 0.22M
Common stock 81.54M - 80.24M 78.95M 74.37M
Capital stock - 81.54M 80.24M 78.95M 74.37M
Retained earnings -79.31201M -79.08362M -80.72806M -78.74396M -76.78666M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.47M 3.11M 4.11M 4.24M 1.57M
Cash and equivalents - - - - -
Total current liabilities 0.17M 0.18M 0.45M 0.24M 0.27M
Current deferred revenue - - - - -
Net debt - - -4.11107M -4.23886M -1.56893M
Short term debt 0.00000M - 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - 4.25M 3.83M 3.79M
Property plant equipment 0.00000M - 0.00497M 0.00550M 0.02M
Total current assets 2.40M 3.19M 4.21M 4.27M 1.63M
Long term investments - - - - -
Net tangible assets - - 3.76M 4.03M 1.38M
Short term investments 1.85M - 0.00000M 0.00000M 0.04M
Net receivables 0.04M - 0.10M 0.03M 0.01M
Long term debt - - - - -
Inventory - - - - -
Accounts payable - 0.12M 0.18M 0.05M 0.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 4.25M 3.83M 3.79M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - 0.00000M 0.00497M 0.00550M 0.02M
Capital lease obligations - - - - -
Long term debt total 0.00000M - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.27744M - 0.04M 0.11M
Change to liabilities - - 0.16M 0.03M -0.02829M
Total cashflows from investing activities 0.45M -0.27744M 0.00000M 0.04M 0.11M
Net borrowings - - - 2.29M -0.04454M
Total cash from financing activities -0.00300M 0.52M 1.85M 4.69M -0.04454M
Change to operating activities - - 0.00952M -0.05307M 0.04M
Net income -0.80296M -2.09556M -2.10766M -1.95730M -1.46059M
Change in cash -2.63919M -1.00266M -0.12778M 2.67M -1.39595M
Begin period cash flow 3.11M 4.11M 4.24M 1.57M 2.96M
End period cash flow 0.47M 3.11M 4.11M 4.24M 1.57M
Total cash from operating activities -0.78525M -1.52330M -1.98629M -1.95656M -1.46152M
Issuance of capital stock - 0.57M 2.15M 2.86M -
Depreciation - - 0.00053M 0.00074M 0.00478M
Other cashflows from investing activities 0.45M -0.27744M 0.00000M 0.04M 0.11M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.01M 0.05M -0.06619M -0.01608M 0.09M
Sale purchase of stock 0.00000M 0.57M 2.15M 2.86M -
Other cashflows from financing activities -0.00300M -0.04926M -0.29907M 1.83M -2.90129M
Change to netincome - - 0.02M -0.04374M -0.15153M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00380M 0.00380M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.00374M -0.21478M 0.03M 0.00169M 0.02M
Stock based compensation - - - - -
Other non cash items 0.02M 0.79M - 1.96M 1.46M
Free cash flow -0.78525M -1.52330M -1.98629M -1.96036M -1.46533M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
1AI
Algorae Pharmaceuticals Ltd		 0.001 7.14% 0.01 - - 2705.69 14.50 3010.88 -3.7154
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.

Algorae Pharmaceuticals Ltd

Rialto South Tower, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Bernard Tuch B.Sc., BSc, FRACP, GAICD, MBBS, MBBS (Hons), Ph.D. Interim Chief Exec. Officer 1951
Mr. Daya Uka Chief Financial Officer NA
Dr. Belinda Di Bartolo Chief Operations Officer NA
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP Company Sec. 1964
Mr. David Richard Hainsworth CEO & Executive Chairman 1973
Mr. Daya Uka B.Com., C.A. Chief Financial Officer NA
Dr. Carolyn M. Sue A.M., B.S., Ph.D. Member of Medical Advisory Board & Chief Medical Officer of NTCELL 1963
Dr. James A. Mckenna Chief Scientific Officer NA
Ms. Leah Pieris Company Secretary NA
Mr. David Richard Hainsworth CEO & Executive Chairman 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.